Abstracts Archive - Page 400 of 2607 - ACR Meeting Abstracts

Abstract Number: 1331 • ACR Convergence 2023
Long-term Effectiveness of a Lifestyle Program for Rheumatoid Arthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial
Carlijn Wagenaar¹, Wendy Walrabenstein¹, Marike Van der Leeden², Franktien Turkstra², Jos W.R. Twisk¹, Maarten Boers¹, Henriët van Middendorp³, Peter Weijs⁴ and Dirkjan van Schaardenburg⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Reade Rheumatology Center, Amsterdam, Netherlands, ³Leiden University, Leiden, Netherlands, ⁴Amsterdam University of Applied Sciences, Amsterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle program, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease…
Abstract Number: 1148 • ACR Convergence 2023
A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome
Ashmia Saif¹, Hafsa Nomani², Frank Hwang², Jie Yang² and Qingping Yao², ¹Stony Brook University Hospital, Syosset, NY, ²Stony Brook University, Stony Brook, NY
Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. Most patients…
Abstract Number: 1302 • ACR Convergence 2023
Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study
Daniel Solomon¹, Olga Demler², Pamela Rist², Leah Santacroce¹, Jon Giles³, Katherine Liao¹ and Joan Bathon³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Columbia University, New York, NY
Background/Purpose: Cardiovascular (CV) disease remains an important source of morbidity and the most common cause of mortality in patients with rheumatoid arthritis (RA). It has…
Abstract Number: 1327 • ACR Convergence 2023
Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Linda Hartman⁴, Judith Oldenkott⁵, Björn Svensson⁶, Ingiäld Hafström⁷, Siegfried Wassenberg⁸, Ernest Choy⁹, John Kirwan¹⁰, Robin Christensen¹¹, Maarten Boers¹² and Frank Buttgereit¹³, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ³Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Charite - University Medicine Berlin, Berlin, Germany, ⁶Lund University, Lund, Sweden, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Rheumazentrum Ratingen, Ratingen, Germany, ⁹Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, ¹⁰University of Bristol, Bristol, United Kingdom, ¹¹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹²Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ¹³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: High-dose glucocorticoids (GCs) can cause weight gain and hypertension. It is unclear whether GCs at ≤7.5mg/day prednisone equivalent ("low dose"), administered for rheumatoid arthritis…
Abstract Number: 1332 • ACR Convergence 2023
Patient-Reported Outcomes, Disease Activity and Safety in 798 Patients with RA Treated with Filgotinib: Up to 1-Year Interim Results from a Prospective Observational Study (FILOSOPHY)
Gerd Burmester¹, Patrick Verschueren², Jerome AVOUAC³, Roberto F. Caporali⁴, Karen Bevers⁵, Neil Betteridge⁶, Thomas P.A. Debray⁷, Francesco De Leonardis⁸, Susana Romero Yuste⁹, Monia Zignani⁸ and James Galloway¹⁰, ¹Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ²Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ⁵Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁶Neil Betteridge Associates, London, United Kingdom, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹⁰King's College London, London, United Kingdom
Background/Purpose: The efficacy of filgotinib (FIL) for treating RA has been demonstrated in clinical trials. Real-world data are valuable to assess patient-reported outcomes such as…
Abstract Number: 1334 • ACR Convergence 2023
Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses
Marina Birck¹, Luck Lukusa², Michal Abrahamowicz³, Gilles Boire⁴, Denis Choquette⁵, Walter P. Maksymowych⁶ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²RI-MUHC, Montreal, QC, Canada, ³McGill University, Verdun, QC, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment safety, particularly malignancy and infections, is an important issue for biologics; hence, surveillance and analyses comparing biosimilar versus bio-originator use in the real…
Abstract Number: 1321 • ACR Convergence 2023
Effect of Subcutaneous Local Anaesthesia Prior to Intra-Articular Injection: An Open Label, Paired-group, Randomized Controlled Trial
Alan Shaji¹, Varun Dhir², Chandra Bhushan Prasad³, Shankar Naidu¹, Aman Sharma⁴, Shefali Sharma⁵, Babita Ghai¹ and Sanjay Jain¹, ¹PGIMER, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³Healthway Hospital, Goa, Zuarinagar, India, ⁴PGIMER, Chandigarh, India, Chandigarh, India, ⁵PGIMER< Chandigarh, Chandigarh, India
Background/Purpose: Intraarticular injections are commonly used both for diagnostic and therapeutic injections of glucocorticoids in patients with inflammatory arthritis. The procedural pain felt by patients…
Abstract Number: 1312 • ACR Convergence 2023
Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry
Ji-Won Kim¹, Ju-Yang Jung¹, Chang-Hee Suh² and Hyoun-Ah Kim¹, ¹Ajou University School of Medicine, Suwon, South Korea, ²Ajou University Hospital, Suwon, South Korea
Background/Purpose: This study aimed to identify risk factors associated with adverse events (AEs) and infections in patients with rheumatoid arthritis (RA) and comorbid interstitial lung…
Abstract Number: 1341 • ACR Convergence 2023
Impact of Ultrasound on Physician Assessments of Patients with RA with Elevated Clinical Disease Activity Scores
Stephanie Song¹, Odette Kolenky¹, Antje Greenfield², Dana Direnzo³, Joshua Baker⁴ and Michael George⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania Health System, Philadelphia, PA, ³University of Pennsylvania, Bala Cynwyd, PA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Treat-to-target is recommended in RA, but physicians often do not escalate therapy despite elevated disease activity measures due to uncertainty regarding the true degree…
Abstract Number: 1160 • ACR Convergence 2023
Antibody Predictors of Prognosis in a Large Multi-centre Cohort of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease
Jennifer Hannah¹, Alexandra Lawrence², Jennifer Martinovic², Marium Naqvi², Saadia Sasha Ali³, Carmel Stock⁴, Cara Owens⁴, Anand Devaraj⁴, Louise Pollard², Sangita Agarwal², Belén Atienza-Mateo⁵, Amit Patel⁶, Alex West², Kate Tinsley², Hasti Robbie⁷, Felix Chua⁴, Boris Lams², Athol Wells⁴, Sam Norton⁷, James Galloway⁷, Elisabetta Renzoni⁴ and Patrick Gordon⁸, ¹King's College London, London, United Kingdom, ²Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ³King's College Hospital, Epsom, United Kingdom, ⁴Royal Brompton and Harefield Hospitals NHS Trust, London, United Kingdom, ⁵Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶King's College Hospital, London, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸NHS, London, United Kingdom
Background/Purpose: IIM-ILD follows a varied clinical course. Serological profile can help predict clinical phenotype, but impact on ILD prognosis is less clear. This multicentre UK…
Abstract Number: 1304 • ACR Convergence 2023
Window of Opportunity to Achieve Better Functional Outcomes in Patients with RA: Effectiveness of an Early Treatment Strategy
Vivian Bykerk¹, Isabel Castrejon², Vibeke Strand³, Stephanie Dahan⁴, Raul Castellanos-Moreira⁵, Leo Chen⁶ and Wayne Little⁴, ¹Department of Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital Universitario Gregorio Marañón, Madrid, Spain, ³Stanford University, Palo Alto, CA, ⁴Bristol Myers Squibb, Princeton, NJ, ⁵Bristol Myers Squibb, Madrid, Spain, ⁶Syneos Health, Vancouver, BC, Canada
Background/Purpose: RA is a chronic disease that can lead to irreversible damage and functional decline with delayed or inadequate treatment.1 Abatacept + MTX is effective…
Abstract Number: 1336 • ACR Convergence 2023
Adalimumab and Etanercept Serum Levels in Rheumatoid Arthritis Patients with and Without a Disease Flare During Tapering
Zohra Layegh¹, Femke Hooijberg², Floris loeff³, lisanne Dijk³, Gaelle vaz³, Theo Rispens³, radboud J.e.m. Dolhain⁴, Gertjan Wolbink⁵ and Pascal de Jong¹, ¹Erasmus medical center, Rotterdam, Netherlands, ²Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Dr. Jan van Breemenstraat 2, 1056 AB, Amsterdam, Netherlands, ³Sanquin Diagnostic Service, Biologics Laboratory, Amsterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: Due to the improved management strategies and availability of biologic disease-modifying antirheumatic drugs (bDMARDs), ~60% of the rheumatoid arthritis (RA) patients will achieve sustained…
Abstract Number: 1326 • ACR Convergence 2023
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 from the SELECT-CHOICE Study
Andrea Rubbert-Roth¹, Koji Kato², Boulos Haraoui³, Maureen Rischmueller⁴, Yanxi Liu², Nasser Khan⁵, Heidi Camp² and Ricardo Xavier⁶, ¹Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ²AbbVie, Inc., North Chicago, IL, ³Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁴The Queen Elizabeth Hospital and Basil Hetzel Institute; Adelaide Medical School, University of Adelaide, Adelaide, Australia, ⁵Pharmacovigilance and Patient Safety, AbbVie, Inc., North Chicago, IL, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: To evaluate the long-term safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, through week 204 in patients with RA from the long-term…
Abstract Number: 1340 • ACR Convergence 2023
Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data
Stephanie Song¹, Michael George², Ted R Mikuls³, Bryant England⁴, Brian Sauer⁵, Grant Cannon⁶ and Joshua Baker², ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Janus kinase inhibitors (JAKi) have demonstrated substantial efficacy in decreasing symptoms and in reducing progressive joint damage in patients with rheumatoid arthritis (RA). In…
Abstract Number: 1268 • ACR Convergence 2023
Clinical Characteristics of Patients with Rheumatoid Arthritis (RA) Who Rate Their Global Assessment of Disease Activity Substantially Lower Than Their Physicians (Negative Discordance) Based on a Large RA Database in Japan: A Rare but Important Subgroup
Tetsuji Sawada¹, Susumu Nishiyama², Shohei Yamashita³, Toshihiro Matsui⁴ and Shigeto Tohma⁵, ¹Tokyo Medical University Hospital, Shinjuku Tokyo, Japan, ²Kurashiki Medical Center, Kurashiki, Japan, ³Tokyo Medical University Hospital, Shinjuku, Japan, ⁴NHO Sagamihara National Hospital, Kanagawa, Japan, ⁵NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: Discordance between patient global assessment (PGA) and physician global assessment (PhGA) regarding the disease activity of rheumatoid arthritis (RA) can be divided into three…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].